# HCK

## Overview
The HCK gene encodes the HCK proto-oncogene, Src family tyrosine kinase, a critical enzyme in cellular signaling pathways. This kinase is predominantly expressed in hematopoietic cells and plays a vital role in immune response, cell growth, and survival. Structurally, HCK is characterized by several domains including an SH4 domain for membrane association, SH3 and SH2 domains for regulatory interactions, and a catalytic tyrosine kinase domain. The protein exists in two isoforms, p59Hck and p61Hck, which differ in their N-terminal sequences and post-translational modifications, affecting their cellular localization and function (Pond2020Membrane; Robbins1995Myristoylation). The intricate regulation of HCK through its domain interactions and modifications underscores its importance in cellular physiology and pathology, making it a significant focus in the study of hematopoietic malignancies and other diseases (Poh2015Hematopoietic; Roversi2017Hematopoietic).

## Structure
The HCK protein, encoded by the HCK gene, is a member of the Src family of tyrosine kinases and exhibits a conserved multidomain architecture characteristic of this family. The protein structure includes an N-terminal SH4 domain responsible for membrane targeting, followed by a unique (U) domain, SH3 domain, SH2 domain, and a catalytic tyrosine kinase domain (SH1), ending with a C-terminal regulatory tail (Johnson2000Modulation; Pond2020Membrane; Alvarado2010Crystal).

The SH4 domain is myristoylated and often palmitoylated, crucial for membrane association (Robbins1995Myristoylation). The SH3 and SH2 domains regulate kinase activity through intramolecular interactions; the SH3 domain binds to the SH2-kinase linker, stabilizing the kinase in an inactive conformation, while the SH2 domain binds to the phosphorylated C-terminal tail (Alvarado2010Crystal). The kinase domain itself is bilobed, with regulatory phosphorylation sites that modulate activity (Johnson2000Modulation).

HCK exists in two splice variant isoforms, p59Hck and p61Hck, differentiated by a 21-residue extension at the N-terminus of p61Hck, affecting their membrane association and localization due to differences in lipid modification (Pond2020Membrane; Robbins1995Myristoylation).

Overall, the structure of HCK is finely tuned through domain interactions and post-translational modifications, enabling its role in cellular signaling pathways.

## Function
The HCK gene encodes the Hematopoietic cell kinase, a protein that is a member of the Src family of tyrosine kinases. This kinase is predominantly expressed in hematopoietic cells, particularly in myeloid and B-lymphocyte lineages, where it plays a critical role in various cellular functions. HCK is involved in the regulation of macrophage phagocytosis, a key process in immune response and cellular debris clearance. It also influences the activation of macrophages, enhancing their ability to produce pro-inflammatory cytokines in response to stimuli, which is essential for an adequate innate immune response (Poh2015Hematopoietic).

In addition to its role in immune response, HCK participates in erythropoiesis and cell survival pathways. It is involved in the erythropoietin/PI3K pathway, crucial for erythroid differentiation, and interacts with the MAPK pathways, influencing the expression of GATA-1, a transcription factor critical for erythroid differentiation (Roversi2017Hematopoietic). The proper regulation of HCK is necessary for normal erythropoiesis, and its dysregulation can lead to increased cell death, contributing to disease progression in conditions like myelodysplastic syndromes and acute myeloid leukemia (Roversi2017Hematopoietic).

## Clinical Significance
HCK, a gene encoding Hematopoietic cell kinase, is implicated in various hematologic malignancies and solid tumors due to mutations, altered expression levels, or disruptions in its normal interactions. In acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL), alterations in HCK expression and activity are linked to disease progression and prognosis. Specifically, reduced HCK activity is observed in AML with specific chromosomal rearrangements and in ALL patients lacking certain fusion proteins, suggesting its role in tumorigenesis by affecting apoptosis (Poh2015Hematopoietic). Additionally, HCK overexpression is noted in de novo AML, where it participates in critical signaling pathways such as PI3K/AKT and MAPK/ERK, influencing cell growth and viability (Roversi2017Hematopoietic).

In the context of solid tumors, HCK has been identified as a potential prognostic biomarker in breast cancer. Studies indicate that higher HCK expression correlates with increased metastasis and poorer survival outcomes, including shorter disease-free survival (DFS) and overall survival (OS) (Zhu2020HCK). Furthermore, HCK's role extends to the tumor microenvironment, where it supports tumor development and progression by promoting processes like phagocytosis, migration, and cytokine secretion in tumor-associated immune cells (Poh2015Hematopoietic).

These findings underscore the clinical significance of HCK in cancer, highlighting its potential as a therapeutic target across various malignancies.

## Interactions
The HCK protein, encoded by the HCK gene, engages in several critical physical interactions with other proteins, influencing various cellular processes, particularly in hematopoietic cells. HCK interacts with the BCR/ABL fusion protein in chronic myeloid leukemia (CML), leading to the activation of STAT5A, PI3K, and AKT signaling pathways, which are crucial for cancer cell growth and survival (Poh2015Hematopoietic). Additionally, HCK binds to the TEL/ABL fusion protein, observed in some CML subsets and acute lymphoblastic leukemias, activating STAT5, ERK, and AKT pathways (Poh2015Hematopoietic).

HCK also interacts with the proto-oncogene product p120 Cbl. This interaction is mediated by HCK's SH3 domain and is essential for the tyrosine phosphorylation of Cbl, a process that enhances various downstream signaling pathways (Howlett1999The; Scholz2000Hck). The phosphorylation of Cbl by HCK facilitates its association with the p85 subunit of PI 3-kinase, particularly following stimulation by lipopolysaccharide (LPS), enhancing macrophage adherence and signaling (Scholz2000Hck).

These interactions highlight the role of HCK in modulating signaling pathways that are pivotal for cell growth, differentiation, and immune responses, underscoring its potential as a therapeutic target in diseases like leukemia.


## References


[1. (Pond2020Membrane) Matthew P. Pond, Rebecca Eells, Bradley W. Treece, Frank Heinrich, Mathias LÃ¶sche, and BenoÃ®t Roux. Membrane anchoring of hck kinase via the intrinsically disordered sh4-u and length scale associated with subcellular localization. Journal of Molecular Biology, 432(9):2985â2997, April 2020. URL: http://dx.doi.org/10.1016/j.jmb.2019.11.024, doi:10.1016/j.jmb.2019.11.024. (11 citations) 10.1016/j.jmb.2019.11.024](https://doi.org/10.1016/j.jmb.2019.11.024)

[2. (Alvarado2010Crystal) John J. Alvarado, Laurie Betts, Jamie A. Moroco, Thomas E. Smithgall, and Joanne I. Yeh. Crystal structure of the src family kinase hck sh3-sh2 linker regulatory region supports an sh3-dominant activation mechanism. Journal of Biological Chemistry, 285(46):35455â35461, November 2010. URL: http://dx.doi.org/10.1074/jbc.m110.145102, doi:10.1074/jbc.m110.145102. (36 citations) 10.1074/jbc.m110.145102](https://doi.org/10.1074/jbc.m110.145102)

[3. (Zhu2020HCK) Xudong Zhu, Yixiao Zhang, Yang Bai, Xi Gu, Guanglei Chen, Lisha Sun, Yulun Wang, Xinbo Qiao, Qingtian Ma, Tong Zhu, Jiawen Bu, Jinqi Xue, and Caigang Liu. Hck can serve as novel prognostic biomarker and therapeutic target for breast cancer patients. International Journal of Medical Sciences, 17(17):2773â2789, 2020. URL: http://dx.doi.org/10.7150/ijms.43161, doi:10.7150/ijms.43161. (13 citations) 10.7150/ijms.43161](https://doi.org/10.7150/ijms.43161)

[4. (Poh2015Hematopoietic) Ashleigh R. Poh, Robert J.J. OâDonoghue, and Matthias Ernst. Hematopoietic cell kinase (hck) as a therapeutic target in immune and cancer cells. Oncotarget, 6(18):15752â15771, June 2015. URL: http://dx.doi.org/10.18632/oncotarget.4199, doi:10.18632/oncotarget.4199. (109 citations) 10.18632/oncotarget.4199](https://doi.org/10.18632/oncotarget.4199)

[5. (Roversi2017Hematopoietic) Fernanda Marconi Roversi, Fernando Vieira Pericole, JoÃ£o Agostinho Machado-Neto, Adriana da Silva Santos Duarte, Ana Leda Longhini, FlÃ¡via Adolfo Corrocher, Bruna Palodetto, Karla Priscila Ferro, Renata Giardini Rosa, Mariana Ozello Baratti, Sergio Verjovski-Almeida, Fabiola Traina, Alessio Molinari, Maurizio Botta, and Sara Teresinha Olalla Saad. Hematopoietic cell kinase (hck) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/pi3k pathway and regulation of erythropoiesis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1863(2):450â461, February 2017. URL: http://dx.doi.org/10.1016/j.bbadis.2016.11.013, doi:10.1016/j.bbadis.2016.11.013. (29 citations) 10.1016/j.bbadis.2016.11.013](https://doi.org/10.1016/j.bbadis.2016.11.013)

[6. (Scholz2000Hck) Glen Scholz, Kellie Cartledge, and Ashley R. Dunn. Hck enhances the adherence of lipopolysaccharide-stimulated macrophages via cbl and phosphatidylinositol 3-kinase. Journal of Biological Chemistry, 275(19):14615â14623, May 2000. URL: http://dx.doi.org/10.1074/jbc.275.19.14615, doi:10.1074/jbc.275.19.14615. (36 citations) 10.1074/jbc.275.19.14615](https://doi.org/10.1074/jbc.275.19.14615)

[7. (Johnson2000Modulation) Timothy M. Johnson, Nicholas A. Williamson, Glen Scholz, Anthony Jaworowski, Richard E.H. Wettenhall, Ashley R. Dunn, and Heung-Chin Cheng. Modulation of the catalytic activity of the src family tyrosine kinase hck by autophosphorylation at a novel site in the unique domain. Journal of Biological Chemistry, 275(43):33353â33364, October 2000. URL: http://dx.doi.org/10.1074/jbc.m002022200, doi:10.1074/jbc.m002022200. (36 citations) 10.1074/jbc.m002022200](https://doi.org/10.1074/jbc.m002022200)

[8. (Robbins1995Myristoylation) Stephen M. Robbins, Nancy A. Quintrell, and J. Michael Bishop. Myristoylation and differential palmitoylation of the hck protein-tyrosine kinases govern their attachment to membranes and association with caveolae. Molecular and Cellular Biology, 15(7):3507â3515, July 1995. URL: http://dx.doi.org/10.1128/MCB.15.7.3507, doi:10.1128/mcb.15.7.3507. (328 citations) 10.1128/MCB.15.7.3507](https://doi.org/10.1128/MCB.15.7.3507)

[9. (Howlett1999The) Christopher J. Howlett, Sabine A. Bisson, Mary E. Resek, Allan W. Tigley, and Stephen M. Robbins. The proto-oncogene p120cblis a downstream substrate of the hck protein-tyrosine kinase. Biochemical and Biophysical Research Communications, 257(1):129â138, April 1999. URL: http://dx.doi.org/10.1006/bbrc.1999.0427, doi:10.1006/bbrc.1999.0427. (25 citations) 10.1006/bbrc.1999.0427](https://doi.org/10.1006/bbrc.1999.0427)